Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
MedCity News
NOVEMBER 18, 2024
The post Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval appeared first on MedCity News. Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin.
Let's personalize your content